Oncosil Medical Ltd - Asset Resilience Ratio
Oncosil Medical Ltd (OSL) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Oncosil Medical Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Oncosil Medical Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Oncosil Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oncosil Medical Ltd (OSL) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Oncosil Medical Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Oncosil Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Oncosil Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
Annual Asset Resilience Ratio for Oncosil Medical Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Oncosil Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$7.15 Million ≈ $5.06 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$6.72 Million ≈ $4.75 Million |
-- |
| 2023-06-30 | 1.02% | AU$116.57K ≈ $82.48K |
AU$11.47 Million ≈ $8.12 Million |
+0.33pp |
| 2022-06-30 | 0.68% | AU$89.27K ≈ $63.16K |
AU$13.07 Million ≈ $9.25 Million |
+0.04pp |
| 2021-06-30 | 0.64% | AU$90.53K ≈ $64.06K |
AU$14.15 Million ≈ $10.01 Million |
+0.35pp |
| 2020-06-30 | 0.29% | AU$69.21K ≈ $48.97K |
AU$24.06 Million ≈ $17.02 Million |
-66.20pp |
| 2019-06-30 | 66.49% | AU$7.76 Million ≈ $5.49 Million |
AU$11.67 Million ≈ $8.26 Million |
-9.98pp |
| 2018-06-30 | 76.48% | AU$15.21 Million ≈ $10.76 Million |
AU$19.88 Million ≈ $14.07 Million |
+8.70pp |
| 2017-06-30 | 67.77% | AU$8.00 Million ≈ $5.66 Million |
AU$11.80 Million ≈ $8.35 Million |
+47.27pp |
| 2016-06-30 | 20.50% | AU$3.26 Million ≈ $2.31 Million |
AU$15.90 Million ≈ $11.25 Million |
-28.07pp |
| 2015-06-30 | 48.57% | AU$3.60 Million ≈ $2.55 Million |
AU$7.41 Million ≈ $5.24 Million |
+3.43pp |
| 2014-06-30 | 45.14% | AU$4.35 Million ≈ $3.08 Million |
AU$9.64 Million ≈ $6.82 Million |
+44.22pp |
| 2013-06-30 | 0.92% | AU$57.35K ≈ $40.58K |
AU$6.24 Million ≈ $4.42 Million |
-2.24pp |
| 2012-06-30 | 3.16% | AU$79.75K ≈ $56.43K |
AU$2.52 Million ≈ $1.79 Million |
-1.50pp |
| 2011-06-30 | 4.66% | AU$141.18K ≈ $99.89K |
AU$3.03 Million ≈ $2.14 Million |
-- |
About Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more